This is my last newsletter as President of The Aesthetic Foundation, and it has been a busy and productive year. Our core mission is to support research that is relevant to practicing plastic surgeons and improve the safety and effectiveness of the procedures that we offer to our patients.
In this month’s update, Dr. Tracy Pfeifer highlights all things The Aesthetic MEET, reflecting on her time as president and how she got involved in The Aesthetic Society, and check out the blooper reel at the end!
In this month’s update, Dr. Tracy Pfeifer highlights all our webinars, like Master Class and AlliedPro Forum, all the travels from New York to Florida, recapping the Facial and Rhinoplasty Symposium and the upcoming The MEET 2026 in Boston!
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and Sodium-glucose cotransporter 2 (SGLT-2) inhibitors are widely used for Type 2 diabetes and weight management but may adversely affect skin quality, resulting in dermal thinning, decreased elasticity, and accelerated aging—a phenomenon referred to as “GLP-1 Face.”
Dr. Tracy Pfeifer highlights key developments for The Aesthetic Society, including the new impact factor for Aesthetic Surgery Journal, evolving needs across generations of surgeons, plans for The Aesthetic MEET 2026, upcoming participation at ISAPS in Singapore, and an important cybersecurity alert for members.